Monday May 13
Isis Pharmaceuticals, Inc. to Present at the 2013 UBS Global Healthcare Conference
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com . A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.
Sun May 12, 2013
1 Healthcare, 1 Basic Materials And 1 Tech Mid Cap With Recent Intensive Insider Selling
There was intensive insider selling in Isis Pharmaceuticals in late April, when the stock was trading above $22. The stock is currently trading at $19.02 or 17.4% below the all time high made in early May.
Fri May 10, 2013
Isis Pharmaceuticals, Inc. Earns $3.5 Million From Biogen Idec, Inc.
The Phase 2 study of ISIS-SMNRx is an open-label, multiple-dose, dose-escalation pilot study, which will include eight infants who have been diagnosed with SMA.
Thu May 09, 2013
Isis Pharmaceuticals Slides A Little Despite Strong Earnings
Isis Pharmaceuticals is a pharmaceutical company that has had quite a wide range of revenues over the past few quarters.
Wed May 08, 2013
ISIS Pharmaceuticals Given New $17.00 Price Target at Canaccord Genuity
ISIS Pharmaceuticals traded down 10.23% on Wednesday, hitting $19.65. ISIS Pharmaceuticals has a 1-year low of $7.54 and a 1-year high of $22.30. The stock's 50-day moving average is currently $18.04. The company's market cap is $2.001 billion.
Isis Pharmaceuticals Prices 9M Share Offering at $19/Share
Isis Pharmaceuticals announced today the pricing of an underwritten public offering of 9,000,000 shares of its common stock, offered at a price to the public of $19.00 per share.
Tue May 07, 2013
Isis Pharmaceuticals's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Good afternoon and welcome to the ISIS Pharmaceutical's First Quarter 2013 Earnings Conference Call.
Mon May 06, 2013
Isis Pharmaceuticals, Inc. Announces the Initiation of a Clinical...
Isis Pharmaceuticals, Inc. Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients With Liver Cancer /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Thu May 02, 2013
Webcast Alert: Isis Pharmaceuticals, Inc.' First Quarter 2013 Financial Results Conference Call
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com . Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.
Sat Apr 27, 2013
Customer Interaction Solutions
Isis Pharmaceuticals initiates Phase II spinal muscular atrophy study
Isis Pharmaceuticals, Inc., a developer of therapeutic drugs inhibiting cell protein synthesis, has initiated a Phase II study of ISIS-SMNRx in infants with spinal muscular atrophy, or SMA.
Wed Apr 24, 2013
ISIS Pharmaceuticals Given New $27.00 Price Target at Stifel Nicolaus
The firm currently has a "buy" rating on the stock. A number of other analysts have also recently weighed in on ISIS.
Tue Apr 23, 2013
ISIS Pharm Begins Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMN[Rx] in infants with spinal muscular atrophy .
Mon Apr 22, 2013
Best Stocks: Biotech Still Holding Top Spots
At StateoftheMarkets.com, we focus our attention on the top-rated stocks of the market for a few simple reasons.